Abstract:Objective: We investigated the effect of intramuscular injections of long-acting bromocriptine in patients with macroadenomas. Study design and patients: Thirty patients with PRL-secreting pituitary macroadenomas were treated with repeated 4-weekly intramuscular injections of 50 or 100 mg of a long-acting, repeatable bromocriptine formulation for six to 37 injections, amounting to a total of 473 injections. Twenty patients received parenteral bromocriptine as primary therapy, ten had persisting hyperprolactinemia after previous therapies including pituitary surgery (n = 7), oral bromocriptine (7), and pituitary irradiation (2). Measurements: A PRL day profile was obtained and the patients' clinical status and history were documented, at intervals. Detailed clinical, laboratory, and radiological (pituitary nuclear magnetic resonance or computed tomography scan) evaluations were performed at baseline, after 1 injection and every 6th injection thereafter. Results: In all patients PRL was suppressed from a mean +/- SEM pretreatment level of 32,620 +/- 8680 to 4480 +/- 1140 mU/I on the third day after the first injection. In 12 patients PRL levels normalized (< 400 mU/I) with the first to fourth injection, in three additional patients PRL levels normalized after 8-15 months. In 19 patients PRL was suppressed to less than 1000 mU/l. In three patients PRL did not decrease to less than 50% of pretreatment; in two of them on oral bromocriptine prior to this study there had been a comparable low efficacy. Of 28 patients with macroadenomas (median height 22 mm) tumour shrinkage was evident in 15 by nuclear magnetic resonance or computed tomography scan 28 days after the first injection, and in three additional patients after 6 months. There was further regression in seven cases after 12, 18 or 24 injections. Adenoma size (mean +/- SEM) decreased to 66 +/- 7% of the pretreatment value. The 40 adverse events noted in 20 of 30 patients during 24 hours after the first injection were similar to known side-effects of oral bromocriptine, nausea and postural hypotension being the most frequent. With repeated injections, on average 0.6 adverse events were noted per injection (mostly mild asthenia). There were no local adverse reactions at the injection site. Conclusion: We conclude that long-acting repeatable bromocriptine in patients with macroprolactinomas offers a safe and efficacious primary treatment that ensures compliance and gives long-term control. Adverse reactions are comparable to oral bromocriptine but subside with repeated injections.

Pleuropulmonary reactions in patients on bromocriptine treatment

[Pleural effusion induced by bromocriptine]

Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease

[Severe pleuropericarditis induced by long-term bromocriptin therapy, report of a case and review of the literature]

Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia

The safety of bromocriptine in long-term use: a review of the literature

Bromocriptine in hyperprolactinemic amenorrhea: a possible early effect on ovarian steroidogenesis

Response of acromegaly to long term bromocriptine therapy: a biochemical and clinical assessment

Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years

The influence of bromocriptine on serum levels of growth hormone and other pituitary hormones and its metabolic effects in active acromegaly

Adjunctive therapy with bromocriptine in Parkinson's disease

Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy

Changes in brain catecholamine metabolism during bromocriptine treatment in polycystic ovary syndrome

Testosterone levels after bromocriptine treatment in patients undergoing long-term hemodialysis

[Effects of bromocriptine on the treatment of prolactinomas in male patients and its influences on their sexual function]

Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine

Long-term treatment of acromegaly with bromocryptine: postprandial HGH levels and response to TRH and glucose administration

Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience

Bromocriptine. Clinical experience in the induction of pregnancy in amenorrhea-galactorrhea syndrome

Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety

Bromocriptine Therapy: Review of mechanism of action, safety and tolerability